For example, we made use of this model to show that selective BRAF-inhibitors (PLX4720 and vemurafenib) are capable of decreasing proliferation, as well as inducing apoptosis in mutant BRAF melanomas, while non-transformed cells were unaffected indicating that therapeutic toxicities in patients may be minimal [6,7]. This evidence concerns the gene BRAF and melanoma.